No abstract available.
Animals ; Genotype* ; Heart-Lung Transplantation* ; Humans ; Mice* ; Tissue Donors*

No abstract available.
Delirium* ; Sweat* ; Sweating*

No abstract available.
Islets of Langerhans* ; Pancreas*

No abstract available.
Tetanus*

No abstract available.
Allografts* ; Anemia, Hemolytic* ; Cadaver* ; Transplantation*

No abstract available.
Leiomyosarcoma ; Vena Cava, Inferior

No abstract available.
Animals ; Killer Cells, Natural* ; Mice*

Over the 1 year 3 month period from 7/11/1997 until 10/30/1998, we have attempted graft salvage with tacrolimus conversion in a total of 11 patients (mean age 41 years, range 31~64 years) with ongoing rejection on baseline CsA immunosuppression after failure of high dose corticosteroid to reverse rejection. The indications for conversion to tacrolimus were ongoing biosy confirmed rejection in all patients. Seven grafts showed vascular rejection and 4 had cellular rejection on biopsy. The median interval to tacrolimus conversion was 4 days (range 1 days to 840 days) after transplantation. Three patients (27.3%) were dialysis-dependent owing to the severity of rejection. All patients (100%) have been successfully rescued and graft function of the patients improved from an average serum creatinine level of 7.3 3.6 mg/dl to 1.4 0.5 mg/dl. During the mean follow-up of 8.1 months after conversion, there were 10 complications following tacrolimus conversion including cytomegalovirus (CMV) infection in 2 patient, herpes esophagitis in 1, aspergillosis pneumonia in 1, pneumocystis carinii pneumonia in 1, new-onset diabetes mellitus in 4, tremor in 1 and bleeding due to thrombocytopenic thrombocytopenic purpura (TTP) in 1. Two of these postconversion complications resulted in patient death. Treatment with tacrolimus may successfully suppress ongoing acute rejection, even if high dose corticosteoid treatment have failed to reverse rejection. Base on these data, we recommend that tacrolimus be used for refractory rejection therapy. An additional anti-infective prophylaxis seems to be necessary in preventing severe complications after rejection therapy.
Allografts* ; Aspergillosis ; Biopsy ; Creatinine ; Cytomegalovirus ; Diabetes Mellitus ; Esophagitis ; Follow-Up Studies ; Hemorrhage ; Humans ; Immunosuppression ; Pneumonia ; Pneumonia, Pneumocystis ; Purpura, Thrombocytopenic ; Tacrolimus* ; Transplants ; Tremor

Pancreas transplantation is primarily performed in type I juvenile onset diabetes mellitus(DM). At present the patients selected for transplantation often have complications such as end-stage renal disease, neuropathy and far advanced retinopathy. These days, the survival of pancreas transplantation for treatment of patients with type I DM has improved especially in simultaneous pancreas and renal transplantation. Various innovations in immunosuppression, management of the pancreatic exocrine secretion, recipient selection and HLA matching have contributed to achieving a reasonable outcome in pancreatic transplantation compared with other organ transplantations. Current improved graft survival has stimulated many centers in the world to become interested in pancreas transplantation program. We successfully performed the first case of simultaneous pancreas and kidney transplantation in our country in August 1992. Until now, 14 cases of pancreas transplantation have been performed in 3 centers, including our 12 cases.
Diabetes Mellitus, Type 1 ; Graft Survival ; Humans ; Immunosuppression ; Kidney Failure, Chronic ; Kidney Transplantation ; Organ Transplantation ; Pancreas Transplantation* ; Pancreas* ; Transplantation ; Transplants

No abstract available.
Animals ; Mice* ; T-Lymphocytes*